Cargando…

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma

High‐grade serous ovarian carcinomas (HGSOCs) were among the tumours with an unsatisfactory outcome of immune checkpoint inhibitors (ICIs). It is imperative to develop feasible biomarker for identifying responsive candidates and guiding precise immunotherapy for HGSOC patients. Here, we analysed gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Ying, Sun, Chengdu, Feng, Yi, Jia, Qingzhu, Zhu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050488/ https://www.ncbi.nlm.nih.gov/pubmed/29855141 http://dx.doi.org/10.1111/jcmm.13678

Ejemplares similares

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements
por: Turashvili, Gulisa, et al.
Publicado: (2020)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
por: Cardenas, Horacio, et al.
Publicado: (2019)

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma
por: Gornjec, Andreja, et al.
Publicado: (2019)

MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary
por: Lee, Cheng-Han, et al.
Publicado: (2009)

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
por: Smith, Philip, et al.
Publicado: (2023)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

BRCA mutation in high grade epithelial ovarian cancers
por: Manchana, Tarinee, et al.
Publicado: (2019)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling
por: Bradbury, Melissa, et al.
Publicado: (2022)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Predictive Modeling Using a Somatic Mutational Profile in Ovarian High Grade Serous Carcinoma
por: Sohn, Insuk, et al.
Publicado: (2013)

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
por: Kang, Hyo Jeong, et al.
Publicado: (2013)

Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
por: Smith, Philip, et al.
Publicado: (2023)

Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation
por: Chong, Gun Oh, et al.
Publicado: (2020)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
por: Mairinger, Elena, et al.
Publicado: (2023)

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
por: Zahari, Mihaela Mărioara, et al.
Publicado: (2021)

Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
por: Shen, Yen Ting, et al.
Publicado: (2019)

Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019
por: Winchar, Kelcey, et al.
Publicado: (2022)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_msaanagm7ekb27cf4ujtfso2bc